Royalty Report: Drugs, Pharmaceuticals, Pain – Collection: 25850

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 9

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 9

Primary Industries

  • Drugs
  • Pharmaceuticals
  • Pain
  • Antibody
  • Cancer
  • Medical
  • Delivery
  • Device
  • Diagnostic
  • Scientific & Technical Instruments
  • Semiconductors
  • Biological Materials
  • Detection
  • Disease
  • Therapeutic

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 25850

License Grant
The University granted the Licensee an exclusive license to  make, have made, use, sell, offer to sell, import, have imported, and otherwise exploit Licensed Products and to practice Licensed Methods.  The inventions, generally characterized as High Dose Capsaicin Relieves Neuropathic Pain (or High Dose Capsaicin for Neuropathic Pain) UCSF Case No. SF00-056.
License Property
Patent Rights means the Regents’ interest in any subject matter claimed in or covered by any of the following Pending U.S. Patent Application Serial No. 08/746,207 entitled Therapeutic Method with Capsaicin and Capsaicin Analogs filed November 6, 1996, the continuation-in-part U.S. Patent Application Serial No. 08/990,633 entitled Transdermal Therapeutic Device and Method with Capsaicin and Capsaicin Analogs filed December 15, 1997 and assigned to The Regents; pending PCT Patent Application Serial No. PCT/US98/25794 of the same title, filed December 8, 1998 and assigned to The Regents; and continuing applications thereof including divisions, substitutions, continuation-in-part applications (but only to the extent however, that claims in the continuation-in-part applications are entitled to the priority filing date of the foregoing applications); any patents issuing on said applications including reissues, reexaminations and extensions; and any corresponding foreign applications or patents based on said applications.
Field of Use
The rights granted apply to the healthcare industry.  Field of Use means all fields and uses.

IPSCIO Record ID: 29361

License Grant
The Licensor grants to the Licensee an exclusive, world-wide License for the commercial development, use, and sale of products generally characterized as “High Dose Capsaicin Relieves Neuropathic Pain”.

The Regents also grants to the Licensee the worldwide right to issue sublicenses.  This Agreement will be in force from the effective date and shall expire upon the last expiration date of a patent Licensed under this Agreement.

License Property
The License includes U.S. Patent Application Serial No. 08/746,207 entitled “Therapeutic Method with Capsaicin and Capsaicin Analogs” filed November 6, 1996, the continuation-in-part U.S. Patent Application Serial No. 08/990,633 entitled “Transdermal Therapeutic Device and Method with Capsaicin and Capsaicin Analogs” filed December 15, 1997.

IPSCIO Record ID: 5728

License Grant
We entered into a non-exclusive, worldwide license agreement with Licensor, an individual,  for U.S. Provisional Patent Application No. 60/006,385 and U.S. Utility Patent Application No. 08/746,207 (U.S. Patent No. 6,248,788) directed to methods of treating neuropathic pain using capsaicin anesthetic, and all applications and patents relating thereto. The licensed technology relates to the use of capsaicin for pain relief. The primary patent underlying the license expires on November 6, 2016. This license agreement makes reference to the August 2001 license agreement between us and Drs. Campbell and Licensor and Mr. Meyer and provides that if Dr. Licensor develops or has any right to any technology under U.S. Patent No. 6,248,788 relating to an injectable product or service using capsaicin and its analogues for pain relief, the technology will be licensed to us pursuant to the terms of the August 2001 license agreement with Drs. Campbell and Licensor and Mr. Meyer.
Field of Use
Field of Use means any human or non-human diagnostic, prophylactic or therapeutic use of the Licensed Patents and Licensed Technology.

IPSCIO Record ID: 238995

License Grant
Licensor grants to Licensee a worldwide, exclusive sublicense under the Regents License to make, have made, use, sell, offer for sale and import the Sublicensed Products in the Sublicensed Field of Use and the Sublicensed Territory for the life of the last to expire patent under the Licensed Patent Rights.
License Property
Licensed Patent Rights shall have the same meaning as Regents Patent Rights under the Regents Option, namely

          (i)   The U.S. Continuation-in-Part application entitled 'Blockade of T Lymphocyte Down-Regulation Associated with CTLA-4 Signaling,' serial number 08/566,853 (U.C. Case No. B96-002-2) filed on December 4, 1995, by Drs. James P. Allison, Dana R. Leach and Matthew Krummel of the University of California at Berkeley and assigned to Regents, that claims priority to Serial Number 08/506,666 (U.C. Case No. B96-002-1, now abandoned) filed on July 25, 1995,

          (ii)  The U.S.. Continuation-in-Part application entitled, 'Blockade of T Lymphocyte Down-Regulation Associated with CTLA-4 Signaling,' serial number 08/646,605 (U.C. Case No. B96-002-3) filed May 8, 1996, by Drs. James P. Allison, Dana R. Leach and Matthew Krummel of the and assigned to Regents and issued as U.S. Patent No. 5,811,097, that is a CIP of Serial Number 08/566,853, which is a U.S. CIP of 08/506,666,

          (iii) The U.S. Continuation-in-Part application entitled, 'Blockade of T Lymphocyte Down-Regulation Associated with CTLA-4 Signaling,' serial number 08/760,288 (U.C. Case No. B96-002-4) filed December 4, 1996, by Drs. James P. Allison, Dana R. Leach and Matthew Krummel of the University of California at Berkeley and assigned to Regents,

          (iv)  PCT International Patent application, Serial Number US96/19375 filed on December 4, 1996, by Drs. James P. Allison, Dana R. Leach and Matthew Krummel and assigned to Regents (U.C. Case No. B93-002/PCT) that claims the convention priority benefits of U.S. Patent Application Serial No. 08/566,853 dating from the U.S. filing date of December 4, 1995, and U.S. Patent Application Serial No. 08/646,605 dating from the U.S. filing date of May 8, 1996, and

          (v)   All other international patents and patent applications, and/or any divisions, continuations, reissues and claims in continuations-in-part that are (a) entitled to the priority filing date of Serial Numbers 08/506,666, 08,566,853, 08/646,605 or 08/760,288 and (b) are claimed or described in Serial Numbers 08/506,666, 08/566,853, 08/646,605 or 08/760,288.

Sublicensed Products means within the Sublicensed Field of Use  

(i)   Any product produced using a Licensed Method, or for use in the practice of a Licensed Method,
(ii)  Any method, process, material or product the manufacture, use or sale of which would be an infringement of any pending claim (were it to issue) or issued claim of the Licensed Patent Rights, or
(iii) Any material, method, process or product, or part thereof, that
      (A) Is covered by a valid claim of any issued, unexpired patent within Licensed Patent Rights. A claim within the Licensed Patent Rights shall be presumed to be valid unless and until it has been held to be invalid by a final judgment of a court of competent jurisdiction from which no appeal can be or is taken, or
      (B) Is covered by any claim being prosecuted in a pending application directed to the Invention (were it to issue).

Invention means the inventions described in 'Blockade of T-Lymphocyte Down-Regulation Associated with CTLA-4 Signaling' as described in Regents Case No. B96-002.

Field of Use
Sublicensed Field of Use means use of the Sublicensed Products that are antibodies (including without limitation, bispecific antibodies, single chain antibodies and/or immunoconjugated antibodies) for all human therapeutic uses permitted by the Regents License.

IPSCIO Record ID: 5727

License Grant
The Inventors, two individuals, hereby grant, jointly and severally, to Licensee an exclusive worldwide and perpetual license to use, license or otherwise exploit the Licensed Technology in the Field of Use, to develop, have developed, make, have made, use, import and sell, have sold and offer for sale Licensed Products and perform Licensed Services, with the right to sublicense with respect to any or all of such recited purposes, provided that such rights as to know-how, proprietary knowledge, information and expertise contained within the Licensed Technology that does not relate solely to the Licensed Patents is licensed hereunder on a nonexclusive basis.
License Property
'Licensed Patents' means U.S. Patent Application No. 09/041294 (U.S. Patent No. 5,962,532) and all applications and products relating thereto directed to methods and kits for relieving pain using capsaicin and an anesthetic.
Field of Use
Field of Use means any human or non-human diagnostic, prophylactic or therapeutic use of the Licensed Patents and Licensed Technology.

The technology licensed under the agreement relates to the steps of administering capsaicin for pain reduction that we use in our product ALGRX 4975.

IPSCIO Record ID: 250347

License Grant
The Licensors grant, jointly and severally, to the Licensee an exclusive, worldwide and perpetual license to use, license or otherwise exploit the Licensed Technology in the Field pain management, for any human or non-human diagnostic, prophylactic or therapeutic use to develop, have developed, make, have made, use, import and sell, have sold and offer for sale Licensed Products and perform Licensed Services, with the right to sublicense with respect to any or all of such recited purposes, provided that such rights as to know-how, proprietary knowledge, information and expertise contained within the Licensed Technology that does not relate solely to the Licensed Patents is licensed hereunder on a nonexclusive basis.
License Property
Methods and compositions for treating pain at a specific site with an effective concentration of capsaicin or analogues thereof.
Field of Use
The Licensee specializes in topical products with pain management applications.

IPSCIO Record ID: 115864

License Grant
The University grants to the Licensee a worldwide license under Licensors Patent Rights to make, have made, use, sell, and distribute Licensed Products and to practice Licensed Method.  The Licensor also grants to the Licensee the right to issue sublicenses to third parties to make, have made, use, sell, and distribute Licensed Products and to practice the Licensed Method.
License Property
The license is for certain inventions, generally characterized as a noninvasive continuous iontophoretic blood monitor/drug delivery system.  Patents relates to devices for iontophoretic non-invasive sampling of substances.

The Licensed Product is any material that is either covered by Licensor’s Patent Rights or any product manufactured using the Licensed Method, in either event to the extent the manufacture, use or sale of which in a particular country infringes an unexpired valid claim of a patent or a pending claim of a patent application under Patent Rights in that country in which such patent has issued or application is pending.

The Licensed Method is any method that is covered by the claims of Licensor’s Patent Rights in the country in which such method is used, or the use or practice of which would constitute, but for the license granted to the Licensee pursuant to this Agreement, an infringement of any unexpired, valid issued claim or pending claim under Patent Rights in that country in which the Licensed Method is used or practiced.

(a) U.S. Patent Application serial no. 150,159, filed 29 Jan 88,(abandoned) by Dr. Richard Guy, et al., and assigned to The Regents;

(b) U.S. Patent Application serial no. 299,397, filed 24 Jan 89, as a continuation-in-part application of (a), (abandoned) by Dr. Richard Guy, et al., and assigned to The Regents;

(c) U.S. Patent Application serial no. 771,483, filed 04 Oct 91, as a continuation-in-part of (b) (now allowed) by Dr. Richard Guy, et al., and assigned to The Regents;

(d) U.S. Patent No. 5,279,543, issued 18 Jan 94, which was a file wrapper continuation application of (b), by Dr. Richard Guy, et al, and assigned to The Regents; and continuing applications thereof including divisions and substitutions but including continuation-in-part applications only to the extent that the claim was supported in the original disclosure; any patents issuing on said application or continuing applications including reissues and extensions; and any corresponding foreign applications or patents.

Field of Use
This agreement pertains to drug delivery systems.  The Licensee, GlucoWatch system is designed to measure glucose frequently, automatically and non-invasively through the ease and convenience of a device worn like a wristwatch.

IPSCIO Record ID: 27499

License Grant
The University hereby grants to the Licensee an exclusive license in the Field of Use, including the right to sublicense under the Patent Rights to make, have made, use, Sell, offer for Sale, import Licensed Products, and to practice the Licensed Method in the United States and in other countries where the University may lawfully grant such licenses.

The University also grant to the Licensee, so long as it retains exclusive rights under this Agreement, the right to issue Sublicenses.

License Property
Whereas, certain inventions are characterized as 'Chemical Nanowire Sensor Arrays' ('Invention');
Whereas, the Invention covered under UC Case Number 2004-177 ('Bio-receptor Embedded Conductive Polymer Nanowire Sensor Arrays');
Whereas, the Invention covered under UC Case Number 2007-108 ('Metal Nanoparticles Decorated Carbon Nanotubes for Gas Sensors');
Whereas, certain of the Inventions covered under UC Case Numbers 2010-170 ('Synthesis of Nanopeapods by Galvanic Displacement of Segmented Nanowires') and 2010-240 ('Metal and Metal Oxides Co-Functionalization SWNT's as High Performance Gas Sensors');

The License was granted within certain fields of use relating to “Bio-receptor Embedded Conductive Polymer Nanowire Sensor Arrays”, “Metal Nanoparticles Decorated Carbon Nanotubes for Gas Sensors”, the “Synthesis of Nanopeapods by Galvanic Displacement of Segmented Nanowires”, “Metal and Metal Oxides Co-Functionalization SWNT’s as High Performance Gas Sensors”, “Ultra-Sensitive Gas Sensors Based on Tellurium-Single Walled Carbon Nanotube Hybrid Nanostructures” and “Selective Nanoscale Asymmetric Gas Sensors”.

The license relates to patented and patent-pending sensor technologies based on nano materials that can detect airborne gases to the parts-per-billion (PPB) level.

'Patent Rights' means the University's interest in the Valid Claims of the United States patents and patent applications, corresponding foreign patents and patent applications and any reissues, extensions, substitutions, continuations, divisions, and continuation-in-part applications (but only those Valid Claims in the continuation-in-part applications that are entirely supported in the specification and entitled to the priority date of the parent application) based on the following

'Bio-receptor Embedded Conductive Polymer Nanowire Sensor Arrays' filed on October 25, 2005, United States Patent Application Serial Number 11/259,557, assigned to The Regents (UC Case Number 2004-177-2);
'Metal Nanoparticles Decorated Carbon Nanotubes for Gas Sensors' filed on September 11, 2007, United States Patent Application Serial Number 12/514,050, assigned to The Regents (UC Case Number 2007-108-2);
'Synthesis of Nanopeapods by Galvanic Displacement of Segmented Nanowires' to be filed shortly and assigned to The Regents (UC Case Number 2010-170); and
'Metal and Metal Oxides Co-Functionalization SWNT's as High Performance Gas Sensors' to be filed shortly and assigned to The Regents (UC Case Number 2010-240).

Field of Use
'Field of Use' means the use of the Licensed Products and the Licensed Methods for chemical detection using carbon nanotube-based sensory arrays. Any use of the Licensed Products for other than chemical detection is excluded from the Field of Use.

The Licensee will try to commercialize patented and patent-pending sensor technologies based on nano materials that can detect airborne gases to the parts-per-billion level to be used in air quality monitoring, explosives detection, industrial plant toxic gas detection, gaseous chemical warfare agent detection, food and agricultural safety hazard detection and other applications.

IPSCIO Record ID: 890

License Grant
The Regents grant to Licensee an exclusive License under Regents' Patent Rights, to make, have made, use, sell, offer for sale and import Licensed Products and to practice Licensed Methods in all Fields of Use to the extent permitted by law.

The Regents also grant to Licensee the right to issue exclusive or nonexclusive subLicenses to third parties.

License Property
REGENTS’ Patent Rights

U.S. Patent Application No. 10/131,384 entitled Estriol Therapy for Multiple Sclerosis and Other Autoimmune Diseases, filed April 24, 2002, which was based on Provisional Application No. 60/286,842 filed 4/25/01 (UCLA Case Nos 1998-531-1,2) by Dr. Voskuhl, and assigned to The Regents.

U.S. Patent Application No. 10/984,364 entitled The Use of Estrial and Other Estranes, Estrogen and Estrogen Receptor Active Compositions in the Treatment of Psoriasis…, filed November 8, 2004, (UCLA Case No. 2004-101-3) by Drs. Rhonda R. Voskuhl, Gerald D. Weinstein and Jenny E. Murase and assigned to The Regents.

Field of Use
Licensed Property Estriol for the treatment of autoimmune diseases & the use of estriol and other estranges, estrogens and estrogen receptor active compositions in the treatment of psoriasis & other autoimmune diseases.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.